Chong Kun Dang Pharmaceutical Corp. has described histone deacetylase 6 (HDAC6) inhibitors reported to be useful for the treatment of cancer, inflammation, neurodegeneration, autoimmune and neurological disorders.

Biolexis Therapeutics Inc. has divulged CDK9/cyclin T1 inhibitors reported to be useful for the treatment of cancer, inflammation and autoimmune disease.

Takeda Pharmaceutical Co. Ltd. has identified orexin OX2 receptor agonists reported to be useful for the treatment of narcolepsy.

North Carolina State University has synthesized vancomycin derivatives containing a 2,3-pyrrolidinedione moiety and reported to be useful for the treatment of bacterial infections.

Gilead Sciences Inc. has disclosed bridged tricyclic carbamoylpyridone compounds reported to be useful for the treatment of HIV infection.

Corbus Pharmaceuticals Holding Inc. has described cannabinoid CB1 receptor antagonists or inverse agonists reported to be useful for the treatment of cancer, dyslipidemia, diabetes, obesity, cardiovascular, inflammatory and liver diseases.

Crossignal Therapeutics Inc. has divulged G-protein coupled receptor GPR35 antagonists reported to be useful for the treatment of cancer.

Alesta Therapeutics BV has identified eukaryotic translation initiation factor 2-α kinase 4 (GCN2) inhibitors reported to be useful for the treatment of cancer.

Uniquest Pty Ltd. has synthesized tyrosine-protein kinase SYK inhibitors reported to be useful for the treatment of allergy, cancer, fungal infections, rheumatoid arthritis, osteoporosis, liver, lung and periodontal diseases, among others.